Amarin Reaches Target Enrollment in Cardiovascular Outcomes Study of VascepaR in Patients With Elevated Triglycerides Despite Statin Therapy

BEDMINSTER NJ and DUBLIN IRELANDMarketwired March 31 2016 Amarin Corporation plc NASDAQ AMRN today announced that target patient enrollment has been reached in its REDUCEIT cardiovascular outcomes trial of Vascepa icosapent ethyl. Amarin also announced ...